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a b s t r a c t
From 2014 to 2017, the World Health Organization convened a working group to evaluate influenza dis-
ease burden and vaccine efficacy to inform estimates of maternal influenza immunization program
impact. The group evaluated existing systematic reviews and relevant primary studies, and conducted
four new systematic reviews. There was strong evidence that maternal influenza immunization pre-
vented influenza illness in pregnant women and their infants, although data on severe illness prevention
were lacking. The limited number of studies reporting influenza incidence in pregnant women and
infants under six months had highly variable estimates and underrepresented low- and middle-income
countries. The evidence that maternal influenza immunization reduces the risk of adverse birth outcomes
was conflicting, and many observational studies were subject to substantial bias. The lack of scientific
clarity regarding disease burden or magnitude of vaccine efficacy against severe illness poses challenges
for robust estimation of the potential impact of maternal influenza immunization programs.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background and overview of World Health Organization
(WHO) working group procedures
Pregnant women and infants under six months of age are
among the population subgroups considered to be at high risk
for serious influenza-related morbidity and mortality [1–10]. As
influenza vaccines are not licensed for use in infants under six
months [11], one strategy for preventing influenza illness in this
age group is maternal immunization during pregnancy [12,13],
an approach that provides both direct protection to pregnant
women and indirect protection of their infants through transpla-
cental antibody transfer [14–16]. Evidence primarily from observa-
tional studies has additionally suggested that maternal influenza
immunization could prevent adverse birth outcomes [17,18]; how-
ever, this remains a topic of scientific debate [19–22].
Despite a 2012WHO recommendation that pregnant women be
prioritized for vaccine receipt in countries initiating or expanding
influenza immunization programs [12], maternal influenza immu-
nization has not been incorporated into routine immunization pro-
grams in many low- and middle-income countries (LMICs) [23]. As
part of a formal strategic review In 2013, Gavi, the Vaccine Alliance
considered an investment in maternal influenza immunization pro-
grams in eligible LMICs but this was not pursued, partly because of
limited data regarding the anticipated impact of such a strategy
[24]. To address this data gap, the WHO Initiative for Vaccine
Research convened a working group in December 2014 [25] with
the following objectives: (i) to determine key parameters needed
for future influenza vaccine impact and health economic modeling
studies, with a focus on immunization of pregnant women in
LMICs; (ii) to determine evidence-based estimates for these key
parameters; (iii) to evaluate the quality of existing data informing
these estimates; and (iv) to recommend future research to address
these gaps.
The working group comprised 30 members, representing all
WHO regions and with diverse expertise in child health; disease
modeling; evidence evaluation methods [26]; health economics;
influenza epidemiology; obstetrics; perinatal epidemiology; and
vaccinology (Appendix A). Three subgroups evaluated evidence
related to influenza epidemiology in pregnant women, infants
under six months of age, and the fetus. Evidence assembled
included existing systematic reviews, randomized clinical trials
(RCTs) of influenza vaccination in pregnancy (three of which were
published during the lifespan of this working group [16,27,28]),
and other publications (e.g., highly-cited studies relevant to influ-
enza virus infection or immunization during pregnancy). The
working group also carried out four new systematic reviews [29–
32]. The objective of this report is to summarize the working group
evidence evaluation and recommendations for research to inform
estimates of maternal influenza immunization program impact.
2. Summary of key findings fromWHO working group-initiated
systematic reviews
The working group procedures used to design and conduct each
new systematic review are summarized in Fig. 1. Briefly, each
review included the development of a structured research
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objective (Table 1); engagement of an experienced medical
librarian to design and execute the literature searches; and appli-
cation of quality assessments to individual studies [33,34] and
across studies using Grading of Recommendations Assessment,
Development and Evaluation (GRADE) criteria [26,35]. Specific
details about the scope of each review, the date of electronic
literature searches, characteristics of included studies, and a
quantitative summary of each review’s findings can be found in
Tables 1–3, and by consulting the original publications [29–32].
We were unable to standardize incidence rate estimates presented
in this report, as the methods used by the primary studies to
calculate them differed. As it is possible that our focused system-
atic reviews could have excluded studies relevant to our working
group objectives, we also evaluated highly-cited, but excluded,
studies on each particular topic to inform our conclusions and
recommendations.
2.1. Review A: Incidence of laboratory-confirmed influenza (LCI)
outcomes among pregnant women [29]
This systematic review of studies published up to February 20,
2015 sought to establish evidence-based incidence estimates of
laboratory-confirmed influenza (LCI) outcomes among pregnant
women (see Table 1 for list of outcomes and Table 2 for character-
istics of included studies) [29]. Among the nine studies that met the
inclusion criteria, six reported data exclusively from the 2009 H1N1
pandemic period, two reported exclusively from seasonal influenza
epidemics, and one study covered both. Almost all (8/9 studies)
were from high-income countries (Table 2). Meta-analysis of inci-
dence rates was not performed due to substantial heterogeneity
and the small number of studies reporting any given outcome. Inci-
dence estimates for symptomatic LCI infection ranged from 0.10 per
10,000 pregnant women (95% confidence interval [CI]: 0.07–0.14)
to 486 per 10,000 pregnant women (95% CI: 375–630), the latter
from the HIV-uninfected and HIV-infected placebo arms, combined,
of an RCT of influenza immunization in pregnant women in South
Africa [16]. Estimates of LCI hospitalization and intensive care unit
(ICU) admission were similarly variable (Table 3), likely due to dif-
ferences in surveillance methodologies and influenza season vari-
ability. LCI mortality in pregnant women was reported by only
four studies, all of which were case series conducted during the
2009H1N1 pandemic. Rates ranged from 0.003 per 10,000 pregnant
women (95% CI: 0.000–0.021) to 0.69 per 10,000 pregnant women
(95% CI: 0.26–1.51), and were based on very low numerator counts
(between one and eight deaths with LCI).
The primary rationale for excluding other commonly-
referenced studies reporting influenza outcomes among pregnant
women was the lack of laboratory confirmation, which was a
pre-specified inclusion criterion for the review. As a general obser-
vation, the excluded studies of influenza-associated outcomes in
pregnant women tended to report rates that were higher than
those described by the studies included in our review, likely
explained by the use of a broad group of non-specific cardiopul-
monary diagnostic codes from health administrative databases,
which could overestimate influenza incidence due to misclassifica-
tion of other influenza-like illnesses as influenza. For example, a
Canadian study estimated that one in 1000 healthy pregnant
women had seasonal influenza-associated hospitalizations per
year, based on administrative diagnostic codes [36]; this rate was
higher than those reported by the studies in our review, all of
which described laboratory-confirmed pandemic influenza
(Table 3). Two additional highly-cited studies [37,38] not only used
administrative diagnostic codes but also focused on trimester-
specific incidence alone, precluding direct comparisons with the
studies in our review. We excluded studies reporting estimated
incidence rates of influenza outcomes and excess burden of
outcomes due to influenza [39] using ecological approaches and
statistical modeling due to the absence of individual-level
laboratory-confirmed data. Typically, these studies used regression
models to analyze data over multiple seasons using influenza
surveillance or administrative databases. This approach has most
commonly been used to estimate excess mortality [40] and respi-
ratory and circulatory hospitalizations in the general US popula-
tion [41]. One such study of pregnant and non-pregnant women
of childbearing age was conducted in South Africa [42], where
baseline maternal mortality rates are higher than in high-income
countries. Between 1999 and 2009, the mean annual seasonal
influenza-associated mortality rate was 12.6 per 100,000 person-
years (95% CI: 7.2–18) among pregnant women, while the
estimated H1N1pdm09 influenza virus-associated mortality rate
was 19.3 per 100,000 person-years (95% CI: 11–27.6) [42], higher
than the rates reported by studies in our review.
Fig. 1. Organizational approach for systematic evidence reviews carried out by theWHOworking group. aAll manuscripts were prepared according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [86].
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Table 1
Objectives for systematic evidence reviews conducted by the WHO working group.
Review A: Incidence of laboratory-confirmed
influenza (LCI) outcomes among pregnant
women
B: Incidence of LCI outcomes among infants
under six months of age
C: Pregnancy as a risk factor for severe outcomes
from influenza virus infection
D: Maternal influenza virus infection and
adverse birth outcomes
Author and citation Katz et al. BMC Pregnancy and Childbirth
2017;17:155 [29]
Fell et al. In press: BMJ Open [30] Mertz et al. Vaccine 2017; 35:521–528 [31] Fell et al. British Journal of Obstetrics and
Gynaecology 2016;124:48–59 [32]
Objective To determine evidence-based estimates of
the incidence of LCI outcomes among
pregnant women
To determine evidence-based estimates of the
incidence of LCI outcomes among infants
under six months of age
To determine whether pregnancy was a risk factor
for severe outcomes of influenza
To assess the association between clinical
influenza disease and/or LCI virus infection
during pregnancy, compared with no
influenza during pregnancy, and adverse
birth outcomes
Date of electronic
literature searches
February 20, 2015 April 19, 2017 April 25, 2014 December 5, 2014
Inclusion criteria  Studies that, regardless of design, other-
wise met criteria in Population, Expo-
sure, and Outcomes (see rows below)
 Additionally, only studies that had labo-
ratory confirmation for influenza virus
infection and included population-based
incidence rates with denominator data
were included
 Studies that, regardless of design, other-
wise met criteria in Population, Exposure,
and Outcomes (see rows below)
 Additionally, only studies that had labora-
tory confirmation for influenza virus infec-
tion and included population-based
incidence rates with denominator data
were included
 Observational studies with a comparator arm of
non-pregnant patients with evidence of influ-
enza virus infection meeting criteria in Popula-
tion, Exposure, Comparison, and Outcomes (see
rows below)
 Ecologic studies, defined as studies that col-
lected data at a group rather than at an individ-
ual level, or in which numerators or
denominators were imputed or estimated
 Comparative observational studies in
humans (i.e., cohort, case-control, cross-
sectional) meeting criteria in Population,
Exposure, Comparison, and Outcomes
(see rows below)
Exclusion criteria  Editorials, commentaries, opinion pieces,
narrative reviews, clinical practice
guidelines, conference abstracts, or liter-
ature not in peer-reviewed journals
 Studies reporting estimated incidence
rates of influenza outcomes and excess
burden of outcomes due to influenza
using ecological approaches and statisti-
cal modeling
 Studies that did not ascertain LCI outcomes
either throughout at least one full influ-
enza season in geographic settings with
defined seasonality, or otherwise for at
least one full year
 Studies reporting estimated incidence
rates of influenza outcomes and excess
burden of outcomes due to influenza using
ecological approaches and statistical
modeling
 Studies where influenza was not examined
as a primary outcome, but rather as a co-
infection in a study population identified
on the basis of another infectious disease
 Non- English articles
 Studies on avian influenza A virus infection in
humans
 Non-English articles, editorials, commen-
taries, narrative reviews, clinical practice
guidelines, conference abstracts or litera-
ture not in peer-reviewed journals
 Case series and case reports (i.e., no com-
parison group of uninfected pregnant
women)
Population Pregnant women Infants under six months of age Pregnant and non-pregnant patients with evidence
of LCI virus infection
Pregnant women
Exposure LCI virus infection LCI virus infection Pregnancy Pregnant women with clinical influenza
disease and/or LCI virus infection
Comparison N/A N/A No pregnancy Pregnant women with no clinical influenza
disease or LCI virus infection
Outcomes  Incidence of LCI infection using serology
 Incidence of symptomatic LCI
 Incidence of LCI hospitalization
 Incidence of LCI ICU admission
 Incidence of LCI mortality
 LCI disability-adjusted life years lost
 Incidence of LCI infection
 Incidence of LCI hospitalization
 Incidence of LCI ICU admission
 Incidence of LCI mortality
Impact of pregnancy on risk of:
 LCI community-acquired pneumonia
 LCI hospitalization
 LCI ICU admission
 LCI-associated mechanical ventilator support
 LCI mortality
Impact of influenza during pregnancy on risk
of: Preterm birth (<37 weeks’ gestation)
 Small-for-gestational-age birth
 Fetal death (miscarriage or stillbirth)
Abbreviations: ICU: intensive care unit; LCI: laboratory-confirmed influenza.
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2.2. Review B: Incidence of LCI outcomes among infants under six
months of age [30]
As the strategy of maternal influenza immunization is also
expected to reduce influenza among infants under six months of
age, we sought to determine incidence rates of LCI outcomes
(Table 1) specifically within this age group [30]. Among 27 primary
studies published up to April 19, 2017 thatmet inclusion criteria, 23
assessed incidence of LCI hospitalization. However, meta-analysis
of study-specific rates was not possible due to high statistical and
methodological heterogeneity. Of the 27 studies, 19 exclusively
covered periods of seasonal influenza, two covered the 2009
H1N1 pandemic period, and six covered both (Table 2). Most stud-
ies were from high-income (55%) or upper-middle income coun-
tries (30%), and no studies originated from low-income countries.
Among US studies, the reported incidence of LCI hospitalization
for infants under six months from influenza seasons between
2000 and 2012 ranged from 9.3 (95% CI: 7.9–10.9) to 91.2 (95%
CI: 67.0–145) per 10,000 infants for seasonal influenza, while the
estimate for H1N1pdm09 influenza was 20.2 per 10,000 infants
(95% CI: 18.1–22.5). Although two non-US studies did not ascertain
any hospitalizations of infants under six months in a few time peri-
ods (i.e., an incidence rate of zero [8,43]), most reported rates of LCI
hospitalization for seasonal influenza that ranged between 6.2 (95%
CI: 3.1–9.3) and 73.0 (95% CI: 40.6–122) per 10,000 infants under
six months, with the exception of an estimated rate of 250 per
10,000 infants (95% CI: 213–292) in one study from China [44]. Of
the nine studies that proposed to capture LCI deaths (Table 3), only
three ascertained any fatal cases among infants under six months.
The most precise rate, from the 2003–2004 influenza season, esti-
mated LCI mortality to be 0.88 per 100,000 infants under six
months of age (95% CI: 0.52–1.39), based on 18 fatal cases with
Table 2
Descriptive characteristics of studies included in systematic evidence reviews carried out by the WHO working group.
Review Total
number
of
included
studies
World Bank country income groupa World Health Organization regionb Type of influenza
A: Incidence of
laboratory-confirmed
influenza (LCI)
outcomes among
pregnant women [29]
9
B: Incidence of LCI
outcomes among
infants under six
months of age [30]
27
C: Pregnancy as a risk
factor for severe
outcomes from
influenza virus
infection [31]
152c,d
D: Maternal influenza
virus infection and
adverse birth
outcomes [32]
21
Abbreviations: AFRO: WHO Regional Office for Africa; AMRO/PAHO: WHO Regional Office for the Americas/Pan American Health Organization; EMRO: WHO Regional Office
for the Eastern Mediterranean; EURO: WHO Regional Office for Europe; SEARO: WHO Regional Office for South-East Asia; WPRO: WHO Regional Office for the Western
Pacific; LCI: laboratory-confirmed influenza.
a World Bank. World Development Indicators. Accessed: 10 Jan 2017. Available at: http://data.worldbank.org/data-catalog/world-development-indicators
b World Health Organization. WHO regional offices. Accessed: 10 Jan 2017. Available at: http://www.who.int/about/regions/en/
c 9 countries were not specified in one of the included studies and, therefore, do not appear in the first two panels [87].
d One of the included studies was a global pooled analysis of 19 countries, which have been individually included in the first two panels [88].
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Table 3
Main results from systematic evidence reviews carried out by the WHO working group.
Review Results
A: Incidence of laboratory-confirmed influenza (LCI)
outcomes among pregnant women [29]
Incidence of LCI infection using serology (3 studies)
 Lowest rate: 483 per 10,000 pregnancies (hospital-based; 1975–1977 influenza seasons)
 Highest rate: 1097 per 10,000 pregnancies (hospital-based; 1993–1994 influenza seasons)
 Modified GRADE assessment [35] of overall evidence quality: very low
Incidence of symptomatic LCI (3 studies)
 Lowest rate: 0.10 per 10,000 pregnancies (hospital/clinic-based; 2009 H1N1 pandemic)
 Highest rate: 486 per 10,000 pregnanciesa (clinic-based; 2011 and 2012 influenza seasons)
 Modified GRADE assessment [35] of overall evidence quality: very low
Incidence of LCI hospitalization (4 studies)
 Lowest rate: 0.04 per 10,000 pregnancies (2009 H1N1 pandemic)
 Highest rate: 7.7 per 10,000 pregnancies (2009 H1N1 pandemic)
 Modified GRADE assessment [35] of overall evidence quality: very low
Incidence of LCI ICU admission (4 studies)
 Lowest rate: 0.01 per 10,000 pregnancies (2009 H1N1 pandemic)
 Highest rate: 6.8 per 10,000 pregnancies (2009 H1N1 pandemic)
 Modified GRADE assessment [35] of overall evidence quality: very low
Incidence of LCI mortality (4 studies)
 Lowest rate: 0.003 per 10,000 pregnancies (hospital/clinic-based; 2009 H1N1 pandemic)
 Highest rate: 0.69 per 10,000 pregnancies (hospital-based; 2009 H1N1 pandemic)
 Modified GRADE assessment [35] of overall evidence quality: very low
Summary:
 Limited number of studies reporting each of the outcomes (no studies reported LCI disability-adjusted
life years lost)
 Meta-analysis of individual study incidence rates was not possible due to high heterogeneity
B: Incidence of LCI outcomes among infants under six
months of age [30]
Incidence of LCI infection (6 studies)
 Lowest rate: 0.75 per 100 person-years <6 months (2011–2014 influenza seasons)
 Highest rate: 35 per 100 person-years <6 months (community-based active household surveillance;
2009 H1N1 pandemic and 2010–2011 infleunza season)
 Modified GRADE assessment [35] of overall evidence quality: low
Incidence of LCI hospitalization (23 studies)b
 Seasonal influenza:
– Lowest rate: 0 per 10,000 infants <6 months
– Highest rate: 250 per 10,000 infants <6 months (2010–2012 influenza seasons)
 H1N1pdm09 influenza:
– Lowest rate: 20.2 per 10,000 infants <6 months
– Highest rate: 259 per 10,000 infants <6 months
 Modified GRADE assessment [35] of overall evidence quality: moderate (across all influenza seasons)
Incidence of LCI ICU admission (7 studies)
 Lowest rate: 0 per 10,000 infants <6 months (2000–2001 influenza season)
 Highest rate: 3.5 per 10,000 infants <6 months (2001–2004 influenza seasons)
 Modified GRADE assessment [35] of overall evidence quality: low
Incidence of LCI mortality (9 studies)
 Lowest rate: 0 per 100,000 infants <6 months
 Highest rate: 5 per 100,000 infants <6 months (hospital-based; 2009 H1N1 pandemic)
 Modified GRADE assessment [35] of overall evidence quality: low
Summary:
 Limited number of studies reporting each of the outcomes, particularly few from non-US settings
 Meta-analysis of individual study incidence rates was not possible due to high heterogeneity
 There was wide variation in incidence rates for LCI hospitalization
 Incidence rates of LCI death among infants under six months were based on few cases (e.g., six out of
nine studies did not ascertain any LCI deaths, and two additional studies documented 2–3 LCI deaths)
C: Pregnancy as a risk factor for severe outcomes from
influenza virus infection [31]
Risk of community-acquired pneumonia in pregnant vs. non-pregnant patients with influenza (8
studies)
 Pooled OR: 1.80 (95% CI: 0.72–4.49)
– Among 3 studies that used women of reproductive age as the comparator: Pooled OR: 1.09 (95% CI:
0.29–4.08)
 GRADE assessment [26] of overall evidence quality: very low
Risk of hospitalization in pregnant vs. non-pregnant patients with influenza (13 studies)
 Pooled OR: 2.44 (95% CI: 1.22–4.87)
– Among 2 studies that used women of reproductive age as the comparator: Pooled OR: 3.28 (95% CI:
0.52–20.6)
 GRADE assessment [26] of overall evidence quality: moderate
Risk of ICU admission in pregnant vs. non-pregnant patients with influenza (47 studies)
 Pooled OR: 0.85 (95% CI: 0.62–1.17)
– Among 10 studies that used women of reproductive age as the comparator: Pooled OR: 0.51 (95% CI:
0.42–0.62)
 GRADE assessment [26] of overall evidence quality: very low
Risk of mechanical ventilator support in pregnant vs. non-pregnant patients with influenza
(26 studies)
 Pooled OR: 1.21 (95% CI: 0.70–2.08)
– Among 8 studies that used women of reproductive age as the comparator: Pooled OR: 0.82 (95% CI:
0.40–1.67)
 GRADE assessment [26] of overall evidence quality: very low
Risk of mortality in pregnant vs. non-pregnant patients with influenza (94 studies)
 Pooled OR: 1.04 (95% CI: 0.81–1.33)
– Among 18 studies that used women of reproductive age as the comparator: Pooled OR: 1.02 (95% CI:
0.57–1.84)
(continued on next page)
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concurrent laboratory detection of influenza virus [10]. Although
the cases were identified through an enhanced national surveil-
lance effort in the United States, some were likely missed as labora-
tory testing is not always performed [10]. The highest rate was
reported from a study of LCI deaths in Buenos Aires during the
2009 H1N1 pandemic; two deaths of infants under sixmonths were
recorded, with a corresponding LCI mortality rate of five per
100,000 infants (95% CI: 0.82–16.1) [45].
Most exclusions of primary studies from our review, that may
have been included by other evidence reviews [46], were due to
non-reporting of data specific to infants under six months of age.
We also excluded studies using the proportion-positive method
of estimating influenza burden. These studies conduct surveillance
for a clinical syndromes such as respiratory hospitalization, often
aggregated over many sites, and report the proportion of samples
that test positive for influenza. This method is sufficiently different
from the primary design in our review (i.e., enumeration of indi-
vidual laboratory-confirmed cases in a defined population) that a
direct comparison of rates was not appropriate.
2.3. Review C: Pregnancy as a risk factor for severe outcomes from
influenza virus infection [31]
The aim of this systematic review of published studies up to
April 25, 2014 was to quantify the risk of severe influenza
outcomes, as listed in Table 1, among pregnant women with LCI ill-
ness relative to other population sub-groups with LCI illness [31].
Only 4% of all studies exclusively covered seasonal influenza
observational periods, and the majority of studies were from
high-income countries (76%; Table 2). Most individual-level stud-
ies enrolled hospitalized subjects (118/142; 83.1%). Pregnant
women had a higher risk of LCI hospitalization than non-
pregnant patients (pooled odds ratio [OR] 2.44; 95% CI: 1.22–
4.87), but among those hospitalized, there was no increased risk
for more severe outcomes such as LCI ICU admission, mechanical
ventilation, or death (Table 3). A sub-group analysis limited to
studies using a comparison group of non-pregnant women of
reproductive age found the risk of ICU admission to be significantly
lower in pregnant women (pooled OR: 0.51, 95% CI: 0.42–0.62),
suggesting that LCI hospitalization of pregnant women may be
partly for precautionary reasons, given their lower likelihood of
ICU admission. There was also no significant difference in LCI mor-
tality of pregnant women once hospitalized (83/94 studies report-
ing mortality only included hospitalized LCI deaths). It is unclear
whether the lack of association between pregnancy and severe
LCI outcomes reflects pregnancy conferring similarly increased risk
as other prevalent conditions in the comparison groups (e.g., car-
diorespiratory disease, obesity, or older age), or whether it was a
result of a lower threshold for hospitalization of pregnant women
compared with other high-risk groups. Follow-up in the included
Table 3 (continued)
Review Results
 GRADE assessment [26] of overall evidence quality: very low
Summary:
 Quality of evidence across studies was poor, with significant heterogeneity between studies for most
analyses
 Influenza during pregnancy resulted in a higher risk of hospitalization than influenza infection in non-
pregnant patients, but among hospitalized patients, the risk of mortality following influenza was similar
in pregnant and non-pregnant individuals
 Whether the reason for hospitalization was severity of illness versus precautionary admission for
obstetrical reasons is unclear
D: Maternal influenza virus infection and adverse birth
outcomes [32]
Maternal influenza during pregnancy and risk of preterm birth (16 studies)
 Across all studies, individual-study relative effect estimates ranged from 0.40 (95% CI: 0.11–1.41) to 4.08
(95% CI: 3.56–4.67)
– Among the 2 highest-quality studies of seasonal influenza, individual-study relative effect estimates
ranged from 0.82 (95% CI: 0.55–1.22) for mild-to-moderate illness, to 1.20 (95% CI: 0.72–2.01) for
severe illness
– Among the 5 highest-quality studies of H1N1pdm09 influenza, individual-study relative effect esti-
mates ranged from 1.03 (95% CI: 0.85–1.25) for mild-to-moderate illness, to 4.00 (95% CI: 2.71–5.90)
for severe illness
 Modified GRADE assessment [35] of overall evidence quality: very low
Maternal influenza during pregnancy and risk of small-for-gestational-age birth (5 studies)
 Pooled OR: 1.24 (95% CI: 0.96–1.59)
– Among 3 estimates of seasonal influenza, individual-study relative effect estimates ranged from
0.71 (95% CI: 0.23–2.20) to 1.66 (95% CI: 1.11–2.49)
– Among 3 estimates of H1N1pdm09 influenza, individual-study relative effect estimates ranged from
0.98 (95% CI: 0.47–2.05) to 1.14 (95% CI: 0.59–2.22)
 Modified GRADE assessment [35] of overall evidence quality: low
Maternal influenza during pregnancy and risk of fetal death (10 studies)
 Two fetal death studies were of sufficient quality and size to permit meaningful interpretation
– Both reported an increased risk of fetal death following maternal H1N1pdm09 influenza: HR = 1.91
(95% CI: 1.07–3.41) for mild-to-moderate illness, and RR = 4.2 (95% CI: 1.42–12.4) for severe illness
 Modified GRADE assessment [35] of overall evidence quality: very low
Summary:
 Meta-analysis of individual study effect estimates was not possible for preterm birth or fetal death due
to high heterogeneity
 Several of the highest-quality studies suggested an association between severe influenza illness during
the 2009 H1N1 pandemic and risk of preterm birth and fetal death
 An important limitation of this literature concerns the potential for different clinical thresholds for
influenza testing/diagnosis/hospitalization among women with high-risk pregnancies or suspected poor
pregnancy outcome, compared with women with low-risk pregnancies. Such differential misclassifica-
tion of the exposure by outcome would be expected to inflate the magnitude of effect estimates, making
influenza disease appear more strongly associated with poor outcome
Abbreviations: CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; HR: hazard ratio; ICU: intensive care unit; LCI:
laboratory-confirmed influenza; OR: odds ratio; RR: risk ratio.
a Based on incidence in the HIV-uninfected and HIV-infected placebo groups combined.
b Four studies reporting LCI hospitalization provided estimates for both seasonal influenza and for H1N1pdm09 influenza.
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studies was not initiated before contact with the healthcare system
and studies did not account for illness severity or co-morbidity.
The review identified important discrepancies between results
from individual-level studies and ecologic studies. The latter
generally reported a higher risk of influenza-associated death and
ICU admission for pregnant women compared with non-pregnant
women [31]. Study designs which estimate risk based on group-
level data are prone to a number of biases [39] and, for this reason,
were excluded from the systematic review. Other commonly-cited
studies were excluded from the review [37,38] as they defined
influenza outcomes according to a broad group of non-specific car-
diopulmonary diagnostic codes from health administrative data-
bases during the influenza seasonwithout laboratory-confirmation.
2.4. Review D: Maternal influenza virus infection and adverse birth
outcomes [32]
The aim of this systematic review of published studies up to
December 5, 2014 was to evaluate the association between mater-
nal influenza illness during pregnancy and adverse birth outcomes
(Table 1) [32]. Among the 21 comparative studies identified, 20 used
observational designs and originated from high-income countries,
14 reported exclusively on seasonal influenza periods, seven
reported exclusively on the 2009H1N1 pandemic, and two reported
on both (Table 2). Individual-study estimates for preterm birth risk
were highly variable (relative risks [RR] ranged from 0.4, 95% CI:
0.11–1.41 to 4.08, 95% CI: 3.56–4.67 [32]). However, when limited
to only the highest-quality studies, two reported significantly
increased preterm birth risk (RR: 2.39, 95% CI: 1.64–3.49 [47] and
RR: 4.0, 95% CI: 2.71–5.90 [48]) associatedwith severe H1N1pdm09
influenza illness requiring hospitalization, while no associationwas
reported by the three studies assessing mild-to-moderate
H1N1pdm09 influenza illness [49–51] nor by the two highest-
quality studies of seasonal influenza [50,52]. There were no signifi-
cant differences in small-for-gestational-age (SGA) birth between
women with and without influenza virus infection during
pregnancy (pooled OR: 1.24, 95% CI: 0.96–1.59) [32]. Although fetal
death (i.e., miscarriage and/or stillbirth) was included as an out-
come by 10 studies, nometa-analysis was possible due to high vari-
ability in fetal death definitions and quality. The two highest-
quality studies reported a significantly increased risk of fetal death
followingmaternal H1N1pdm09 influenza disease (RR 1.91, 95% CI:
1.07–3.41 for mild-to-moderate disease [49] and 4.2, 95% CI: 1.42–
12.4 for severe disease [48]). Vaccine RCTs can provide complemen-
tary evidence relating disease to non-specific clinical outcomes [53],
which is useful to consider in this context given the low-quality,
mixed evidence from observational studies. We included one
placebo-controlled RCT [16] in our review, in which the risk for pre-
term birth computed from raw study data did not differ between
treatment arms, though the trial was not powered for this sec-
ondary outcome.
As this review considered only comparative studies (i.e., compar-
ing birth outcomes amongwomenwith andwithout influenza virus
infection during pregnancy), case series studies were excluded.
With the exception of a few individual studies [54–56], previous
reviews showed that most of these case series studies reported
higher than expected rates of pregnancy loss and preterm birth
among infected pregnant women [57–59], especially series of hos-
pitalized women [57,60–62]. Notwithstanding the limitations of
case series [63], the existing descriptive studies of influenza disease
during pregnancy are more geographically diverse and offer addi-
tional contextual information about the clinical course of influenza
illness during pregnancy, prevalence of maternal comorbid condi-
tions (e.g., asthma, HIV co-infection), and other sociocultural factors
that may affect both treatment and prevention. Taken together,
the findings from our review and the excluded descriptive studies
agree that pregnant womenwith severe H1N1pdm09 influenza dis-
ease requiring hospitalization appeared to have an increased risk of
preterm birth and fetal death, though the limited data preclude firm
conclusion on the magnitude. We did not find convincing data that
mild maternal influenza virus infection was associated with any of
the adverse birth outcomes mentioned above.
Table 4
Vaccine efficacy (VE) results from randomized controlled trials (RCT) of influenza immunization during pregnancy.
Location Bangladesh South Africaa Mali Nepal
Reference Zaman et al. [15] Madhi et al. [16] Tapia et al. [27] Steinhoff et al. [28]
NEJM 2008;
359:1555–64.
NEJM 2014; 371:918–31. Lancet ID 2016; 16:1026–35. Lancet ID 2017; pii: S1473-3099(17)
30252–9.
[Epub: 2008 Sep17] [Epub: 2014 Sep 4] [Epub: 2016 May 31] [Epub: 2017 May 15]
Type of control Active
(pneumococcal
polysaccharide
vaccine)
Placebo Active (quadrivalent
meningococcal conjugate
vaccine)
Placebo
Population 340 women in the
third trimester of
pregnancy
2116 HIV-negative women in the second or
third trimester of pregnancy (20–36 weeks
of gestation)
4193 women in the third
trimester of pregnancy
(28 weeks of gestation)
3693 women in the second or third
trimester of pregnancy (17–34 weeks
of gestation)
Attack rate of symptomatic LCI illness in mothers
Vaccine arm –b 1.8%c 0.5%c 1.7%c
Control arm –b 3.6%c 1.9%c 2.4%c
VE against LCI
virus illness
in mothers
–b 50% (95% CI: 14–71)c 70% (95% CI: 42–86)c 31% (95% CI: 10 to 56)c
23% (95% CI: 43 to 58)d
Attack rate of symptomatic LCI illness in infantsc
Vaccine arm 0.7% 1.9% 2.5% 4.1%
Control arm 1.8% 3.6% 3.8% 5.8%
VE against LCI
virus illness
in infants
63% (95% CI: 5–85) 49% (95% CI: 12–70) 33% (95% CI: 4–54) 30% (95% CI: 5–48)
Abbreviations: CI: confidence interval; LCI: laboratory-confirmed influenza; RCT: randomized controlled trial; VE: vaccine efficacy.
a Summary and results refer to non-HIV infected women.
b Outcome measured in mothers was not LCI illness, but influenza-like illness defined as any respiratory illness with fever.
c Measured up to 24 weeks post-delivery.
d Measured up to the delivery.
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3. Results from other evidence assembled by the WHO working
group
3.1. Vaccine efficacy against LCI infection in pregnant women and
newborns
Three RCTs of influenza immunization during pregnancy were,
or became, available for review by the working group, originating
from Bangladesh [15], South Africa [16] and Mali [27]. A fourth
trial from Nepal [28] was published as this report was being pre-
pared, and a Cochrane review [64] is currently being updated to
incorporate this new evidence. Table 4 presents vaccine efficacy
(VE) estimates for prevention of LCI infection in mothers and
infants up to six months of age from the RCTs. VE against LCI infec-
tion among pregnant women over six months of follow-up was
70% (95% CI: 42–86) in Mali [27] and 50% in South Africa (95%
CI: 14–71) [16], but not statistically significant in the recent RCT
from Nepal (VE: 31% for all LCI in the combined cohort, 95% CI:
10 to 56) [28]. Among infants followed from birth to six months
of age, VE estimates ranged from 30% (95% CI: 5–48) in Nepal [28]
to 63% (95% CI: 5–85) in Bangladesh [15].
3.2. Influenza vaccination and birth outcomes
The majority of studies of maternal influenza immunization and
birth outcomes are observational epidemiologic studies and origi-
nate from high-income countries. Two published systematic
reviews on this subject were available when the WHO working
group was convened in 2014 [18,65]. One review included 27 com-
parative studies assessing the association between maternal influ-
enza immunization and preterm birth and fetal death up to April
2014 [18]. No safety concerns were identified, as none of the stud-
ies reported an increased association between influenza vaccine
receipt and adverse outcomes. To the contrary, studies generally
reported either no association or significant risk reductions for pre-
term birth (ranging from 14% to 37%) and late fetal death (ranging
from 34% to 56%), which the authors cautioned could be attributed
to important methodological limitations identified in many of the
primary studies [18]. Another review of 19 studies published up
to March 2014 [65] also concluded that there was no evidence to
suggest any adverse effect of influenza vaccination during preg-
nancy on congenital anomalies or fetal death, but noted the limited
number and quality of available studies.
Two methodological evaluations [19,66] and a WHO expert
consultation [22] recently explored issues related to the interpre-
tation of observational studies reporting beneficial effects of
maternal influenza immunization on adverse birth outcomes. In
brief, existing observational studies have numerous limitations in
study design and analytical methods [19]. The most compelling
explanation for any large protective effect of influenza vaccination
on adverse birth outcomes in observational studies is residual con-
founding due to preferential selection of vaccination by pregnant
women with a more favorable health profile who, in turn, may
be less likely to have an adverse birth outcome. This phenomenon
has been well documented in observational studies of influenza
vaccination in elderly adults [67,68]. Moreover, one study that
modeled data using a range of plausible scenarios for rates of influ-
enza illness during pregnancy, vaccine effectiveness, and vaccine
uptake, showed that the protective benefits of influenza vaccina-
tion for an outcome such as preterm birth would be expected to
be very small and, thus, difficult to detect [66]. Taken together with
what is known about the multi-factorial etiology of most adverse
birth outcomes, it seems unlikely that influenza immunization
would produce an improvement in birth outcomes to the magni-
tude observed by some observational studies [22].
RCT results with respect to birth outcomes have also been
mixed. In secondary analyses among a subset of 116 infants born
during the influenza season, the trial conducted in Bangladesh
found significantly higher mean birth weight (190 g, 95% CI: 9–
378) and a lower percentage of SGA infants (37% reduction, 95%
CI: 0–60) born to influenza-vaccinated women compared with
infants born to women vaccinated with pneumococcal polysaccha-
ride vaccine [69]. The recently-published trial from Nepal, the only
RCT to include low birth weight (defined as <2500 g) as a primary
outcome [28], also found an increase in mean birth weight (influ-
enza vaccine arm: 2803 g, placebo arm: 2761 g; 42-g increase,
95% CI: 8–76) corresponding to a 15% reduction in low birth weight
(95% CI: 3–25) among infants born to influenza-vaccinatedmothers
compared with infants in the placebo group. However, there were
no differences in SGA or preterm birth. In contrast, the two trials
from Africa did not detect any differences in preterm birth [16],
low birth weight [16,27], or mean birth weight [16,27] between
treatment groups overall or when assessed by maternal influenza
infection status [70] or birth during the influenza season [27]. It
remains unclear whether the divergent findings resulted from pro-
tocol differences [71], or due to geographical differences in influ-
enza biology and/or baseline maternal-newborn health status.
4. Interpretation
Across the evidence compiled by this working group, the fol-
lowing general observations can be made:
 Apart from the four influenza vaccine RCTs, which were con-
ducted in Bangladesh [15], South Africa [16], Mali [27], and
Nepal [28], LMICs were substantially under-represented among
the primary publications included in each of the four WHO-
initiated reviews, with much of the data originating from the
United States in particular;
 With the exception of LCI hospitalization among infants under
six months of age, limited influenza incidence data were avail-
able for seasons outside of the 2009 H1N1 pandemic period;
 A low number of studies, combined with high clinical, design
and statistical heterogeneity, precluded quantitative meta-
analysis in three of the four reviews initiated by the working
group; and
 The overall quality of evidence in the working group-initiated
systematic reviews, as assessed using the GRADE approach,
was generally considered low to very low for most outcomes
(Table 3).
WHO has noted that policy-makers from LMICs are likely to
place higher value on vaccines with demonstrated impact on sev-
ere influenza disease [72]. Thus, incidence estimates of influenza
disease are essential for informing vaccine policy, investment deci-
sions, and quantifying the potential impact of influenza vaccina-
tion programs on important public health outcomes [73,74]. Our
systematic reviews of LCI incidence rates in pregnant women
[29] and infants under six months [30] found a limited number
of studies, a wide range of estimates in incidence rates, and limited
representation from LMICs where disease burden and severity may
differ due to differences in influenza epidemiology, access to care,
testing resources and practices, and background prevalence of
underlying comorbid diseases such as HIV infection. A 2015 Bill
and Melinda Gates Foundation convening of experts in maternal
immunization reached a similar conclusion concerning the lack
of robust influenza data to support financial and policy decisions,
particularly for LMICs [75]. Given the predominance of high-
income country studies, study results may be affected by access
to high-quality medical care. Estimates from a systematic review
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of influenza in young children indicate a higher burden among
infants under one year of age in LMICs compared with high-
income countries [46]. The lack of more definitive baseline influ-
enza disease burden estimates, including vaccine-preventable dis-
ease incidence against severe clinical outcomes such as pneumonia
or respiratory disease mortality [53], poses challenges for estimat-
ing the public health impact of incorporating maternal influenza
immunization into national programs.
Similarly, evidence on the association between maternal influ-
enza virus infection and adverse birth outcomes is necessary for
clarifying expectations for improvement in these outcomes follow-
ing influenza immunization [19,76]. Despite a small number of
high-quality studies suggesting an association between severe
H1N1pdm09 influenza disease and preterm birth and fetal death,
the magnitude of increased risk is unclear [32]. It also remains
unclear whether adverse events were specific to H1N1pdm09 virus
exposure or more generally to influenza virus exposure. Moreover,
the observational evidence that maternal influenza immunization
reduces the risk of such adverse birth outcomes is inconsistent
and of limited quality. Recent examinations of the plausibility of
this phenomenon recommend that studies suggesting that mater-
nal vaccination has a substantial beneficial effect on adverse birth
outcomes such as preterm birth or fetal death should be inter-
preted with caution [19,22,66]. The clinical significance of the
42-g increase in birth weight found in the recent Nepal study
[28] deserves further investigation. Despite uncertain data on vac-
cine impact on adverse birth outcomes, there is nevertheless
strong and consistent evidence that influenza immunization dur-
ing pregnancy prevents influenza virus infection both in pregnant
women and their infants, and thus should continue to serve as a
primary guide for vaccine policy and investment strategies.
5. Recommendations
This WHO working group was initiated to review and interpret
the evidence base used for global policy and funding decisions con-
cerning maternal influenza immunization programs. The working
group synthesized the current evidence on this topic (Table 3)
and identified numerous evidence gaps (Table 5). Specific recom-
mendations relating to each of the four systematic reviews carried
out by the working group can be found in Table 5. Finally, we offer
the following general research recommendations:
 Best practices standards for the design, conduct, analysis, and
reporting of influenza surveillance among pregnant women
and infants under six months, along with uniformly-defined
outcome measures and safety measures (e.g., recent Brighton
Collaboration and STROBE recommendations [77,78]), would
help improve study quality and comparability.
 Global standards for influenza surveillance recommend specific
age groupings for reporting of data which include 0 to <2 years
[79]. Recommendations to report disease data for infants under
six months of age would facilitate systematic reviews and com-
parisons of results most relevant to maternal influenza immu-
nization strategies.
 More geographically diverse and higher-quality studies are
needed. The literature is dominated by case reports and case
series published during the 2009 H1N1 pandemic. While these
are important to alert medical and public health professionals
about groups with unexpected risks, they are extremely limited
in their ability to quantify disease risk or incidence, especially
outside of pandemic time periods. Well-designed, multi-year
comparative studies (disease risk) or population-based
Table 5
Summary of remaining gaps in the evidence and WHO working group recommendations for future research.
Review Evidence gaps and recommendations
A: Incidence of laboratory-confirmed influenza (LCI)
outcomes among pregnant women [29]
Evidence gaps:
 Few studies describe incidence rates of LCI outcomes in pregnant women, particularly from seasonal
epidemics
 No studies were identified from low-income countries
Recommendations:
 Future incidence studies should be conducted using consistent, high-quality surveillance methods
 Studies from LMICs and during seasonal epidemics should be a priority
B: Incidence of LCI outcomes among infants under six
months of age [30]
Evidence gaps:
 Limited number of incidence studies in this policy-relevant age group
 Limited number of studies were identified from LMICs
 Few studies evaluated LCI mortality, and few events were ascertained in studies assessing this outcome
Recommendations:
 High-quality population-based surveillance of LCI outcomes in infants under six months should be con-
ducted, particularly in LMICs
C: Pregnancy as a risk factor for severe outcomes from
influenza virus infection [31]
Evidence gaps:
 Limited evidence from influenza seaons other than 2009 H1N1 pandemic period
 Limited evidence from LMICs
 As a whole, current studies could not distinguish between whether pregnant women with influenza
were hospitalized due to disease severity or for precautionary reasons related to concerns for fetal well-
being
Recommendations:
 A longitudinal study where a community-derived cohort of pregnant and non-pregnant women of
reproductive age with LCI influenza infection are prospectively followed for severe LCI outcomes
D: Maternal influenza virus infection and adverse birth
outcomes [32]
Evidence gaps:
 Evidence is imbalanced with RCTs coming from LMICs, while observational studies are from high-
income countries
 Lack of evidence on the possible interaction between stage of pregnancy and influenza infection on
adverse birth outcomes
 Limited evidence of the impact of influenza other than H1N1pdm09 influenza on birth outcomes
 Limited evidence on the impact of influenza serotype on fetal death
Recommendations:
 Future high-quality studies should be conducted to assess the impact of maternal seasonal influenza
infection during pregnancy on birth outcomes
– A multi-site/multi-national study should be considered to be able to identify less common adverse
birth outcomes, such as fetal death or congenital anomalies
– Ideally, LCI illness should be used as the study exposure, with ascertainment of the gestational tim-
ing of the infection
Abbreviations: LCI: laboratory-confirmed influenza; LMICs: low- and middle-income countries.
D.B. Fell et al. / Vaccine 35 (2017) 5738–5750 5747
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on January 20, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
surveillance with systematic case ascertainment (disease inci-
dence) are required, particularly from LMICs.
 As data on LCI outcomes from resource-poor countries may
exist but remain unpublished [46], and many studies of LCI out-
comes among infants have not reported data on infants under
six months of age separately, efforts should be directed toward
aggregating these existing data before embarking on new stud-
ies in this age group.
 Phase IV clinical trials conducted to inform WHO policy recom-
mendations should consider more severe illness endpoints, as
these are the most important outcomes for many decision mak-
ers in LMICs [72]. Vaccine probe studies that include severe ill-
ness endpoints among pregnant women and young infants as
well as measurement of all potentially important outcomes
regardless of influenza confirmation (e.g., all-cause acute lower
respiratory tract infection hospitalization [80]) would be espe-
cially useful to quantify the public health benefit of influenza
vaccine programs [53,81]. However, we acknowledge that vari-
able vaccine effectiveness and the large sample size required for
studies of severe outcomes could make this approach unfeasible
for logistic and financial reasons.
 Given limitations in the evidence base, we were unable to gen-
erate definitive pooled estimates for most of the key parameters
pursued by this working group. Moreover, expected high
heterogeneity across influenza seasons, geographies, and popu-
lations would suggest that no single estimate of each parameter
will sufficiently inform impact and economic models. Our
evidence-based reviews can, however, be used to provide a
range of inputs for future impact and economic models, which
should employ a probabilistic approach to generate outputs, tai-
lored to the different context-specific geographical and socio-
economic factors of interest to policy makers.
6. Conclusion
This working group conducted an extensive review of disease
burden related to maternal influenza immunization and concluded
that available data are currently insufficient to estimate the poten-
tial impact of maternal immunization programs on severe influ-
enza illness, particularly from LMICs. However, it is worth noting
that there are broader potential benefits of an influenza vaccine
program in pregnant women not considered by the working group.
Influenza epidemics result in substantial economic costs and pre-
vention of influenza illness can decrease ambulatory care visits,
inappropriate antibiotic prescribing, and work/school absenteeism
[12]. We did not attempt to quantify these additional impacts of
influenza but they are important considerations for policy makers
reviewing influenza programs. For most LMICs, maternal influenza
immunization programs are the most programmatically feasible
given the relative strength of antenatal care as an immunization
platform [82]. Moreover, integration of immunization and health
care services can improve healthcare delivery overall [83,84], sug-
gesting that a Gavi investment in maternal immunization may
have additional benefits to antenatal care overall [24]. Lastly, coun-
tries that have systems to regulate, procure, and distribute sea-
sonal influenza vaccines will be better able to respond to a future
influenza pandemic [85]. There are many potential benefits to a
maternal influenza immunization program and more effort is
needed to quantify their full public health value to inform vaccine
policy and investment decisions.
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